Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.68 |
| ▸ | DPP7 | Q9UHL4 | 8/20 | 0.68 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.68 |
| ▸ | DPP4 | P27487 | 6/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655957 | 0.89 | ACE (0.58) | DPP8DPP7DPP9DPP4HDAC8 | |
| Hydrochloric Acid SCHEMBL9032178 | 0.88 | HDAC8 (0.60) | DPP8DPP7DPP9DPP4HDAC8 | |
| SCHEMBL21746415 | 0.82 | DPP9 (1.00) | DPP8DPP7DPP9DPP4 | |
| SCHEMBL21156689 | 0.82 | DPP9 (1.00) | DPP8DPP7DPP9DPP4 | |
| SCHEMBL4779078 | 0.81 | DPP8 (0.71) | DPP8DPP7DPP9DPP4HDAC8 | |
| SCHEMBL4779080 | 0.81 | DPP8 (0.71) | DPP8DPP7DPP9DPP4HDAC8 | |
| SCHEMBL4775064 | 0.80 | DPP7 (0.66) | DPP8DPP7DPP9DPP4HDAC8 | |
| SCHEMBL4775055 | 0.80 | DPP7 (0.66) | DPP8DPP7DPP9DPP4HDAC8 | |
| SCHEMBL4122444 | 0.79 | NOTUM (0.52) | DPP8DPP7DPP9DPP4HDAC8 | |
| SCHEMBL14655984 | 0.76 | DPP8 (0.51) | DPP8DPP7DPP9DPP4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | DPP8 3805/4885DPP7 3990/4885DPP9 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.